candidiasis%20(pediatric)
CANDIDIASIS (PEDIATRIC)
Candida sp are the most common cause of fungal infections.
It can manifests from benign mucocutaneous illnesses to invasive process that may affect any organ.
It is considered as normal flora in the gastrointestinal & genitourinary tracts, but when there is an imbalance in the ecological niche they can invade & cause disease.
The immune response of the patient is the important determinant of the type of infection caused by Candida.
Most common risk factors include: prematurity, very low birth weight, use of broad-spectrum antibiotics use, use of central venous catheters, receipt of parenteral nutrition, receipt of renal placement therapy by patients in intensive care unit (ICU), neutropenia, use of implantable prosthetic devices and receipt of immunosuppressive agents.
Drug Information

Indication: Invasive aspergillosis; fluconazole-resistant serious invasive Candida infections (eg, C krusei); serious...

Indication: For adult & childn ≥12 mth: Empirical therapy for presumed fungal infections in febrile, neutropenic pa...

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Invasive candidiasis in childn & adults. Oesophageal candidiasis in adults, adolescents ≥16 yr & el...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

Indication: Invasive aspergillosis in patients w/ disease refractory to amphotericin B or intolerant to these drugs. Fusar...

Indication: Cap: Vulvovag & oral candidosis; dermatomycosis, plantar tinea pedis & palmar tinea manus, pityriasis ...

Indication: Tinea pedis, cruris, corporis & versicolor; cutaneous candidiasis.

Indication: Acute or recurrent genital & vag candidiasis, candidal balanitis, dermatomycosis including tinea pedis, ti...

Indication: Cryptococcosis ie, cryptococcal meningitis & infections of other sites (eg, pulmonary, cutaneous). Mainten...

1  /  8
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 27 Jun 2019

A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.